Loading
NASDAQHealthcareBiotechnology
Latest quote
$117.56
−$0.99 · -0.84%
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Previous close
$117.56
−$0.99 · -0.84%
Regular session · ET · Market data may be delayed.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Day range
Current $117.56
52-week range
Current $117.56
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Sentiment
63
Bullish
Risk
47
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Day range
Current $117.56
52-week range
Current $117.56
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 9.9B USD | 13.01M USD | 5.6M USD | 7.59M USD | 6.49M USD |
| Selling, general, and administrative | 6.8B USD | 3.16M USD | 3.23M USD | 2.95M USD | 2.63M USD |
| Operating expenses | 16.7M USD | 16.16M USD | 8.83M USD | 10.54M USD | 9.13M USD |
| Interest income | 2.99M USD | 404.02K USD | 429.04K USD | 21.24K USD | 24.02K USD |
| Operating income | −16.7M USD | −16.16M USD | −8.83M USD | −10.54M USD | −9.13M USD |
| Net income | −13.72M USD | −15.59M USD | −8.4M USD | −10.52M USD | −9.1M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI17.31M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 ETFIWM13.74M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Extended Market ETFVXF4.9M0.01%93.7B USD0.05%$242.66+0.14%
iShares Russell 2000 Value ETFIWN3.69M0.03%14.47B USD0.24%$224.62+0.40%
Vanguard Russell 2000 ETFVTWO2.74M0.02%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC1.8M0.12%1.47B USD0.60%$196.25+0.69%
Vanguard U.S. Momentum Factor ETFVFMO1.7M0.08%1.8B USD0.13%$229.8+0.93%
iShares Russell 2000 Growth ETFIWO1.22M0.01%14.58B USD0.24%$377.54+0.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard U.S. Momentum Factor ETFVFMOiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
